Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. Mark R. Hutchins

Hematology Oncology
4004 Pioneer Woods Dr, 
Lincoln, NE 
Accepting New Patients
Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)
4004 Pioneer Woods Dr, 
Lincoln, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Hutchins is a Hematologist Oncology provider in Lincoln, Nebraska. Dr. Hutchins is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Paget Disease of the Breast, Multiple Myeloma, Inflammatory Breast Cancer, Lung Cancer, and Bone Marrow Aspiration. Dr. Hutchins is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in NE
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

4004 Pioneer Woods Dr, Lincoln, NE 68506

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Veliparib, Carboplatin
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
View 3 Less Clinical Trials

1 Total Publications

Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy.
Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy.
Journal: Anticancer research
Published: September 04, 2016
Similar Doctors
Julie M. Vose
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Julie M. Vose
Hematology Oncology | Hematology | Oncology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Julie M. Vose
Hematology Oncology | Hematology | Oncology

Unmc Physicians

Emile 42nd St, 
Omaha, NE 
 (47.4 miles away)
402-559-4015
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Julie Vose is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Vose is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vose is currently accepting new patients.

James O. Armitage
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. James O. Armitage
Hematology Oncology | Hematology | Oncology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. James O. Armitage
Hematology Oncology | Hematology | Oncology

Unmc Physicians

Emile 42nd St, 
Omaha, NE 
 (47.4 miles away)
402-559-4015
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

James Armitage is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Armitage is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Endoscopy. Dr. Armitage is currently accepting new patients.

Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Philip J. Bierman
Hematology Oncology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Philip J. Bierman
Hematology Oncology
988102 Nebraska Medical Ctr, 
Omaha, NE 
 (47.4 miles away)
402-559-9800
Languages Spoken:
English

Philip Bierman is a Hematologist Oncology provider in Omaha, Nebraska. Dr. Bierman is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hutchins's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 74 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile